LLE-aCD371

LLE-aCD371 is an experimental therapeutic candidate developed by LLE Therapeutics, designed to target Acute Myeloid Leukemia (AML). It utilizes the company's proprietary Lipid-Like Envelope (LLE) technology, which consists of nanoparticle-based delivery vehicles. LLE-aCD371 is specifically engineered with a targeting moiety against CD371 (CLEC12A), a cell surface marker highly expressed on AML blasts and leukemic stem cells (LSCs) but absent on healthy hematopoietic stem cells. By targeting CD371, the drug aims to deliver its therapeutic payload—typically mRNA—directly to malignant cells, thereby inducing apoptosis or inhibiting cell growth while sparing healthy bone marrow. This approach is intended to address the high relapse rates in AML by eliminating the reservoir of leukemic stem cells.

Other names

anti-CD371 LLEanti-CD-371 LLEanti-CD 371 LLECD371-targeted lipid-like envelopeCD-371-targeted lipid-like envelopeCD 371-targeted lipid-like envelope